Acadia Pharmaceuticals
Mid Cap · Healthcare · Biotechnology
$28.25−$0.13 (-0.46%)
Acadia Pharmaceuticals
Mid Cap · Healthcare · Biotechnology
$28.25−$0.13 (-0.46%)
Stock analysis
Get the AI take on ACAD
Track it to unlock the price chart, verdict and what could change it.
- ✓Live price chart
- ✓A clear accumulate, trim or avoid call
Free to track. No card required.
Stock Fundamentals & Key Indicators
52-week range
Low$19.69
High$28.35
Today $28.25
RSI (14)
61.2Neutral
03070100
Overall score
59/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
- ✓5 years of revenue, profit and cash flow
- ✓Valuation and balance-sheet checks
- ✓Business and geographic mix
- ✓Analyst targets and recommendation trend
Free for 3 days, then $9/mo. Cancel anytime.
Analyst Rating and Sentiment
Analyst price targets
Lowest
$17
Current price
$28.25
Median target
$36
Highest
$45
LowHigh
Operating Record
Revenue
What's working
- Cash exceeds debt by $882.6M, leaving a net cash buffer, a good sign.
- ROIC: Money put back into the business keeps coming back out as profit, a hallmark of a durable moat.
What to watch
- Forward P/E: The price already assumes strong earnings growth that still has to show up.
- EV / EBITDA: The price leans on operating earnings that haven't materialized.
What the market charges
Forward P/E
Needs attention · 86% above avg
35.49x
Price / sales
Reasonable · Priced reasonably against its revenue
4.27x
Price / FCF
Reasonable · Priced a bit rich against its cash flow
33.41x
EV / EBITDA
Rich · Operating earnings don't yet support this price
40.48x
How efficiently it compounds
ROIC
Strong · Comfortably clears the bar for efficient capital use
19.8%
ROE
Favorable · 37.3% - strong capital efficiency
35.7%
Debt / equity
Favorable · 0.04 - strong leverage
0.06x
Current ratio
Strong · Comfortable room to cover bills due within a year
3.39x
Peer Comparison
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $4.87B | 12.7 | +11.8% | 59 |
 | $11.53B | 22.0 | +19.7% | 78 |
 | $4.60B | 13.9 | +13.5% | 77 |
 | $33.87B | 35.4 | +15.5% | 77 |
 | $1.11T | 40.1 | +49.6% | 76 |